Physician profile
George A Roussel
NPI 1821026535
$707.40
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $707.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $185.06 | 2019 | |
| Amgen INC. | $140.88 | 2019 | |
| Novartis Pharmaceuticals Corporation | $109.94 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.19 | 2019 | |
| Sanofi-Aventis U.S. LLC | $45.25 | 2019 | |
| Merck Sharp & Dohme LLC | $42.43 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.33 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $26.29 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.65 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.75 | 2019 | |
| Astellas Pharma US INC | $12.70 | 2019 | |
| Melinta Therapeutics, LLC | $12.63 | 2019 | |
| Pfizer INC. | $12.30 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Roussel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.